Fibrin-related markers (FRMs) such as fibrin and fibrinogen degradation products (FDPs), D-dimer, and soluble fibrin monomer complex (SFMC) were prospectively evaluated in 522 patients using the overt disseminated intravascular coagulation (DIC) diagnostic criteria. The differences in all FRMs between the DIC group and the non-DIC group, and those between the survivors and nonsurvivors were significant in the patients with infections. In an analysis of all patients, DIC score cutoff values of 2 and 3 points for FDP, D-dimer, and SFMC were recommended to be 8.3 and 42.0 mg/mL, 2.4 and 22.0 mg/mL, and 3.4 and 138.0 mg/mL, respectively. In conclusion, the adequate cutoff value is thus considered to be useful for both making a diagnosis of DIC and for predicting the outcome. Fibrin-related markers are therefore thought to be more useful for making a diagnosis of DIC based on infections than based on any other underlying disorders.
Introduction
Disseminated intravascular coagulation (DIC) is often found in patients with infections, leukemia, and solid tumors. 1, 2 In infectious DIC, microvascular dysfunction, depression of antithrombin (AT) and protein C, and elevated plasminogen activator (PA) inhibitor I (PAI-I) are frequently present. [3] [4] [5] Therefore, hypercoagulation without hyperfibrinolysis are usually observed in septic DIC. 6, 7 High levels of tissue factor (TF) and PA are detected in some leukemic or solid cancer cells, 8, 9 and both hyperfibrinolysis and hypercoagulation are observed in DIC due to leukemia or the presence of solid cancers. There are several differences among the pathophysiologies of DIC due to these 3 underlying diseases and the hemostatic abnormalities are different among the 3 underlying diseases.
Two diagnostic criteria for DIC have been established by the Japanese Ministry of Health and Welfare (JMHW) 10 and another by the International Society of Thrombosis and Haemostasis (ISTH). 2 The ISTH overt DIC criteria tend to focus on septic DIC, but the other criteria established by the JMHW tend to diagnose the condition based on the presence of various underlying diseases. The JMHW and ISTH diagnostic criteria include global coagulation tests, such as the prothrombin time (PT), platelet count, fibrinogen, and fibrin and fibrinogen degradation products (FDPs) or D-dimers, which are primarily used for the scoring of hemostatic abnormalities. In particular, the score of both the diagnostic criteria for fibrin-related markers (FRMs) such as FDP, D-dimer, and soluble fibrin monomer complex (SFMC) is important for the diagnosis of DIC. However, the cutoff values of FRMs are not the same between the two different sets of criteria, and each marker needs to be standardized to improve the accuracy of the diagnosis.
In this study, 522 patients with infections, solid cancers, or hematopoietic tumors were prospectively evaluated using the DIC diagnostic criteria established by ISTH and JMHW, and the usefulness of FRMs were examined for DIC associated with the 3 underlying disease states (infections, solid cancers, or hematopoietic tumors).
Materials and Methods
A total of 522 patients in 9 institutes with underlying disorders known to be associated with DIC were registered for this prospective study on the DIC diagnostic criteria between January 1, 2005 and May 31, 2008. The study protocol was approved by the Human Ethics Review Committee of the Mie University School of Medicine and a signed consent form was obtained from each participant. This study has been faithfully carried out in accordance with the Declaration of Helsinki. The inclusion criteria were based on the presence of one or more of the following laboratory findings: a platelet count of less than 120 Â 10 3 /mL; FDP of more than 10 mg/mL; fibrinogen of less than 100 mg/dL; and a PT ratio of over 1.25. Any patients with symptoms associated with thrombotic thrombocytopenic purpura and heparin-induced thrombocytopenia, antiphospholipid syndrome, or with severe liver injuries were excluded from this study. There were 238 patients with infectious diseases (83 females and 155 males, median age: 71 years; age range 62-77 years), 132 with solid cancers (43 females and 89 males, 64 years; 54-72 years), and 152 with hematologic tumors (67 females and 85 males, 62 years; 45-72 years) who were included in the study. Disseminated intravascular coagulation was diagnosed using the ISTH overt DIC diagnostic criteria 2 or JMHW DIC diagnostic criteria. 10 The treatment for DIC 7 including AT, heparin, low-molecularweight heparin, gabesate mesilate, nafamostat mesilate, or danaparoid sodium were carried out under the observation of the individual physicians after blood sampling was obtained at registration. The patients who were alive at 28 days after the registration were considered to be survivors and those who died by 28 days were considered to be nonsurvivors.
The PT, fibrinogen, platelet count, and FDP were measured at each of the institutes based on the methods reported in numerous previous studies. [11] [12] [13] An FDP assay at each institute correlated well with the LPIA FDP (Mitsubishi Chemical Medience Corporation, Tokyo, Japan). The plasma levels of SFMC 14 and D-dimer were measured by a latex immune agglutination test using Auto LIA FM (Roche Diagnostics, Tokyo, Japan) and the LATECLE D-dimer (Kainos, Tokyo, Japan), respectively, in the central research laboratory, SRL Inc (Tokyo, Japan).
Statistical Analysis
The data are expressed as the medians (95% confidence interval [CI]). The differences between the groups were examined for statistical significance using the Mann-Whitney U test. A P value of less than .05 was considered to be statistically significant. All statistical analyses were performed using the SPSS II software package (SPSS Japan, Tokyo).
Results
Out of 522 patients, 66 patients with infections, 48 with solid cancers, and 63 with hematopoietic tumors were diagnosed to have DIC based on the diagnostic criteria of the JMHW. 10 Regarding the FRMs, FDP, D-dimer, and SFMC were significantly higher (P < .001, respectively) in all patients with DIC than in those without DIC ( Figure 1 and Table 1 ). The differences in all FRMs between the DIC group and the non-DIC group were significant (P < .001) in the patients with infections but not in those with solid cancers (Table 1) .
Cutoff values of 2 points (moderate increase) and 3 points (strong increase) according to the ISTH overt-DIC diagnostic criteria were adopted as the 2.5th percentile with the 95% confidence interval (CI) and median of patients with DIC (Table 1) . For all FRMs of solid cancers or SFMC in each of the disease groups, the value of the 2.5th percentile was similar between the DIC group and the non-DIC group, and a cutoff value of 2 points for the FRMs could not be determined for solid cancers. In addition, the cutoff value of 2 points for the SFMC could not be determined for any of the 3 diseases (Table 2 ). In the analysis of all patients, the cutoff values of 2 points for FDP, D-dimer, and SFMC were 8.3 mg/mL, 2.4 mg/mL, and 3.4 mg/mL, respectively, while the cutoff values of 3 points were 42.0 mg/mL, 22.0 mg/mL, and 138.0 mg/mL, respectively. The cutoff values of the FRMs were slightly different among the participants with the 3 different types of underlying diseases, and for all 3 categories. The concordance in the diagnosis of DIC between JMHW and ISTH overt DIC diagnostic criteria was relatively high in patients with infections but low in patients with hematopoietic tumors, but the concordance of exclusion for DIC between the JMHW and ISTH overt DIC diagnostic criteria was high ( Table 3 ).
The differences in the FDP, D-dimer, and SFMC between the survivors and nonsurvivors were significant in all patients (Figure 2 ; P < .001) and in the patients with infections (P < .001, P < .01, and P < .001, respectively; Table 4 ) but not in the patients with either solid cancers or hematopoietic tumors. In the analysis of the receiver operating characteristic curve (ROC) for the diagnosis of DIC, the area under the curve (AUC) of the FRMs was high in patients with infections, but slightly lower in those with solid cancers, while the AUC of FDP was higher in hematopoietic tumors ( Table 5 ). In the analysis of the ROC for predicting a poor outcome, the AUC of the FRMs was high in patients with infections but not in patients with solid cancers and hematopoietic tumors.
Discussion
Fibrin-related markers are very important markers for making a diagnosis of DIC, but the cutoff values of FRMs have not yet been clearly established in ISTH overt DIC diagnostic criteria. 2, 4 In this study, FDP, D-dimer, and SFMC levels were significantly higher in all patients with DIC than in those without DIC, thus confirming that the FRMs are the most useful marker for the diagnosis of DIC. However, the significance of the differences for all FRMs between the DIC group and the non-DIC group was different among the participants with infections, solid cancers, and hematopoietic tumors, and it was significantly different in the patients with infections. These results were similar to those of previous reports. 4, 6 In the analysis of cutoff values of 2 points and 3 points for the ISTH overt DIC diagnostic criteria, the FDP, D-dimer, and SFMC levels in patients with solid cancers or the SFMC for each disease category showed the value of the 2.5th percentile to be similar between the DIC group and non-DIC group, thus indicating that the cutoff value of 2 points was not useful in solid cancers or for SFMC in the patients with all 3 underlying diseases. These results confirm that patients with solid cancers are in a hypercoagulable state, 15, 16 and it is therefore difficult to diagnose DIC in patients with solid cancers. The SFMC levels are so sensitive for thrombosis 14, 17 that this marker may not be able to differentiate between mild DIC and non-DIC. Both FDP and D-dimer are related to hyperfibrinolysis, however, SFMC is not affected by hyperfibrinolysis. As a result, SFMC in this study was measured by a latex immune agglutination test not using a PA. In the cutoff values recommended from this study, the cutoff values of 2 and 3 points for FDP were similar to the 1 and 3 points utilized in the JMHW criteria, 10 and the cutoff values for D-dimer were higher than those in previous report. 18, 19 Although the cutoff values of FRMs were slightly different among the patients with the 3 different underlying diseases, it is easy to use these cutoff values for the analysis of all 3 diseases. The cutoff value in 2 points (moderate increase) and 3 points (strong increase) of ISTH overt DIC diagnostic criteria adopted the value of 2.5% in 95% CI and median of patients with DIC (Table 1) . ''-'' means that the cutoff value is not useful, because the values of 2.5% in patients with DIC and those without DIC were similar. Data were rounded off.
The diagnosis of DIC based on the ISTH overt DIC criteria using this cutoff value had a higher concordance with DIC based on the JMHW criteria in comparison to using the other cutoff value.
Using the cutoff values from this study, the concordance of the diagnosis of DIC between the JMHW and the ISTH overt-DIC diagnostic criteria was similar to that described in previous reports, 20 and it was also relatively high in patients with infections and low in those with hematopoietic tumors, however the concordance of exclusion for DIC was high. These results confirm that the diagnostic criteria for DIC proposed by the JMHW are more sensitive than those proposed by the ISTH. In this study, markedly elevated FRM levels were able to predict a poor outcome in the patients with infections, but not in those with solid cancers or hematopoietic tumors, thus suggesting that DIC may be related to a poor outcome in patients with infections but not in those with solid cancers or hematopoietic tumors. 4 Activated protein C and AT improved the mortality in the septic patients with DIC. 21, 22 In patients with infections, the diagnosis of DIC using an adequate cutoff value of FRMs will be therefore useful for predicting the outcomes in such patients.
In conclusion, the appropriate cutoff value is slightly different for the diagnosis of DIC among the participants with the above described 3 different underlying diseases and this value will be useful for both making a diagnosis of DIC and predicting the outcome in such patients. Fibrin-related markers are more useful for the diagnosis of DIC based on infections than based on other underlying disorders. 
